













Motor noise is rich signal in autism research and pharmacological treatments





Sample raw head motions extracted from rs-fMRI data and corresponding speed profiles with kinematics landmarks of interest (peaks marked by open circles).  (A) Displacement and rotation kinematics extracted using SPM8 from raw resting-state image files (NifTI format) provided in ABIDE (yielding 3 positional and 3 orientation parameters) . Representative ASD participant’s linear displacements and angular rotations of the head registered with respect to the first frame. Speed profiles obtained by computing the Euclidean norm of each 3 dimensional velocity vector   displacement at each point of application  from frame to frame, for 300 frames . To obtain velocity vector fields with corresponding speed scalar temporal profiles, the position data was analyzed using different methods and the results compared. One method filtered position data using a triangular filter to preserve the original temporal dynamics of the first rate of change data (i.e. the original timing of the peaks) while smoothing the sharp transitions from frame to frame 1 (using triangular window for velocity v of frame i, k summation index from –d to d and testing various values of d e.g. up to 6, to build a symmetrically weighted sum around the center point, frame by frame). We also used regular derivative functions in the Matlab spline toolbox to transition from position to velocity. We obtained similar results as those with the triangular filter presented in the main text. (B) Representative control data. Notice the differences in magnitude between these two representative participants. For clarity the speed data of the control is not plotted at the same scale of the ASD panel so as to be able to see the patterns (notice that there is a large difference in the y-axis scale from A to B).
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Table 1. The results for each study-site statistical comparison of the noise levels.
Study Site	Median [range]Delta error	Ranksum Wilcoxon	N participantsN scans/participant
UM_1	ASD          0.82 [0.79, 1.69]TD  0.54 [0.52, 0.16]		ASD 55, TD 55, 300
UM_2	ASD          0.81 [0.69, 1.55]TD  0.57 [0.54, 1.69]		ASD 13, TD 22, 300
USM	ASD         0.65 [0.65, 0.68]TD 0.46 [0.46, 0.48]		ASD 53, TD 48, 240


Table 2. Outcome of the Kolmogorov-Smirnov non parametric two-sample test on the empirically estimated cumulative distribution functions (CDFs) of the average linear speed around speed maxima taken from minima-to-minima (as in Supplementary Figure 2 inset) when comparing 2 vs. 3 medication classes (1) ASD participants ‘on’ medication vs. TD controls; (2) ASD participants ‘on’ medication vs. medication-naive ASD participants; (3) medication-naive ASD participants vs. TD controls. Medication sub-groups are formed by participants with ASD who were ‘on’ medication, with reported intake of either 2 or more, or 3 or more medications from distinct medication classes. Note that “3 or more” group contains some participants from the “2 or more” group. 
	Comparison Type
Number of medications (ASD, N)	(1)	(2)	(3)
Two medications                   (38)	 5.7494e-37	 0.0053	4.3440e-65





Table 3. Psychotropic medications taken by participants with ASD shown by medication class, and their reported motor and bodily related side effects. 
Class(Psychotropic medications, N)	Specific medications(across the 7 sites)	Motor and Bodily Related Side Effects	N *(Main study-sites: UM_1,UM_2)	N **(study-sites: NYU, UCLA_1, OLIN, PITT)
Antidepressants (10)	Fluoxetine, Sertraline hydrochloride, Trazodone, Escitalopram, Citalopram, Bupropion, Mirtazapine, Duloxetine hydrochloride, Venlafaxine, Paroxetine	Tremors; paraesthesia; dizziness, drowsiness 	17	36
Stimulants (5)	Amphetamine and Dextroamphetamine, Lisdexamfetamine, Methylphenidate Extended release, Dexmethylphenidate, Dextroamphetamine sulfate	Dizziness, drowsiness; twitching; convulsions	14	30
Anticonvulsants (3)	Oxcarbazepine, Valproic acid, Lamotrigine	Tremors; drowsiness	2	2
Atypical antipsychotics (5)	Risperidone, Ziprasidone hydrochloride, Asenapine, Quetiapine, Aripiprazole	Tremors, twitching; restlessness	12	14
Benzodiazepine anticonvulsant (1)	Lorazepam	Drowsiness; muscle trembling	0	1
Alpha agonists (2)	Guanfacine, Clonidine	Restlessness; shakiness; dizziness	3	7
Atypical ADHD medication (NRI) (1) 	Atomoxetine	Tremors; dizziness, drowsiness	6	5
Nonbenzodiazepine sedative-hypnotic (1)	Eszopiclone	Clumsiness; difficulty with coordination	0	1
Nonbenzodiazepine anxiolytic (1) 	Buspirone	Nervousness	2	0

Note: paraesthesia is the sensation of itching, burning, numbness, prickly feeling on the skin, or the feeling of “pins and needles”. Note that these totals do not add up to N=92 (the number of ASD participants “on” medication across all sites) because some ASD participants were taking multiple medications from different classes, and some were taking multiple medications belonging to the same class. (Medication class information was missing for N=5 participants who were reported as taking psychotropic medication; these participants’ data are not part of this Table). Across the six reporting sites, participants with ASD were taking Antidepressants (N=53; includes SSRIs, NRIs, SARI and atypical antidepressants), Stimulants (N=44), Atypical antipsychotics (N=26), Anticonvulsants (N=4), Benzodiazepine anticonvulsant (N=1), alpha agonists (N=10), Atypical ADHD medication (N=10; NRI), nonbenzodiazepine sedative-hypnotic (N=1), nonbenzodiazepine anxiolytic (N=1).  (None of the TD participants were on psychotropic medications, except one, whose data were excluded from medication-specific analyses). *In the main sample, there were N=11 unique participants in the ASD group on atypical antipsychotics medication (whereas N=1 was on two antipsychotic medications). Note that one study-site, USM, did not report medication intake. **In the complementary sample, there were N=28 unique participants on stimulants (N=2 were on two different stimulants). There were N=29 unique participants on antidepressants (N=5 on two antidepressant medications and N=1 on 3 antidepressant medications). Sources of reported side effects for each medication class: https://www.nlm.nih.gov/medlineplus/druginformation.html (​https:​/​​/​www.nlm.nih.gov​/​medlineplus​/​druginformation.html​), http://www.drugs.com (​http:​/​​/​www.drugs.com​), and http://www.medicinenet.com (​http:​/​​/​www.medicinenet.com​).  

Additional information is provided in References  ADDIN EN.CITE 7-15. 


Table 4. Outcome of the Kolmogorov-Smirnov non parametric two-sample test on the empirically estimated cumulative distribution functions (eCDFs) of the average linear speed around speed maxima when comparing (1) ASD participants ‘on’ medication vs. TD controls; (2) ASD participants ‘on’ medication vs. medication-naive ASD participants; (3) 39 medication-naive ASD participants vs. 52 TD controls. Data for normative comparisons (N=52) are from a single site (UM_1) with the longest total scan time and the largest number of TD participants with a known medication-free status. Each medication class group is formed by participants with ASD where the medication class is composed of one or more medications in that class and is taken as part of a ‘combination treatment’.

Class in a combination-treatment	Comparison Type
Medication Class (ASD, N)	(1)	(2)	(3)
Antidepressant                     (46)	4.2786e-117	8.9180e-32	4.3440e-65
Anticonvulsant                     ( 4)	3.3807e-35	0.0088	
Alpha Agonist                      (10)	1.4938e-21	0.3168	
Atypical ADHD                   (10)	0.0027	2.3692e-19	
Atypical Antipsychotic        (26)	6.0632e-05	5.2869e-18	
Stimulant                              (42)	1.0531e-37	4.7917e-05	

Table 5. Outcome of the Kolmogorov-Smirnov non parametric two sample test on the empirically estimated cumulative distribution functions (eCDFs) of the average linear speed of the head micro-movements when comparing (1) ASD participants ‘on’ medication vs. TD controls; (2) ASD participants ‘on’ medication vs. medication-naive ASD participants; (3) medication-naive ASD participants vs. TD controls. Each medication class group is formed by participants with ASD where the medication class is composed of one or more medications in that class and is taken in isolation. The participant does not take other medications from a different class.

Class in isolation	Comparison Type
Medication Class (ASD, N)	(1)	(2)	(3)
Antidepressant                      (16)	4.5896e-52	1.1652e-13	4.3440e-65
Atypical ADHD                    (  4)	1.2987e-05	1.5284e-14	
Atypical Antipsychotic         (  7)	2.1210e-05	3.4403e-05	








Inclusion/exclusion criteria for each site are reported in detail at http://fcon_1000.projects.nitrc.org/indi/abide/.  Each site included data for individuals with Autism Spectrum Disorders (ASD) and typically developing (TD) individuals. Note that reported criteria are similar, but are not fully uniform across the seven sites used in the current study (listed in detail below). Briefly, typically developing (TD) control participants were required to be neurologically and psychiatrically healthy individuals, ascertained on the basis of detailed health questionnaire and family history at most sites. Potential participants with Autism Spectrum Disorders (ASD) at most sites were excluded if there was a history of a neurological disorder, history of seizures, or previous head trauma with loss of consciousness. Of note, USM performed genetic testing to ensure exclusion of medical causes of autism (e.g., Fragile-X gene testing). In determining whether potential participants meet criteria for inclusion in the ASD group, all seven sites used the Autism Diagnostic Observation Schedule (ADOS-G)  ADDIN EN.CITE 16 and the parent interview, Autism Diagnostic Interview-Revised (ADI-R)  ADDIN EN.CITE 17, as well as additional criteria that varied across sites (e.g., meeting the DSM-IV-TR diagnosis of autism, Asperger’s or Pervasive Developmental Disorder Not-Otherwise-Specified (PDD-NOS)). All participants were required to have intelligence quotient (IQ) scores over 70. Sites-specific criteria are as follows.

Exclusion criteria. Exclusion criteria for all potential participants (ASD and TD) common to all 7 sites included contraindications to MRI (including the presence of metal implants, tattoos, pacemaker, braces, or pregnancy) and previous head trauma with loss of consciousness. In addition, potential participants were excluded at UM_1, UM_2, USM, UCLA_1, and PITT if they had any neurological disorder or history of seizures. UCLA_1 site also excluded potential participants with tic or involuntary movement disorder, or any known genetic disorder. NYU site excluded potential participants with chronic systemic medical conditions. 

Exclusion criteria for ASD participants. In addition, reported exclusion criteria for potential ASD participants included the presence of psychosis or bipolar disorder at UM_1 and UM_2. Potential ASD participants at the NYU site were excluded if they had a manic/depressive episode, bipolar disorder, schizophrenia, or posttraumatic stress disorder, as well as if they were on antipsychotic medication. PITT excluded potential ASD participants with genetic disorder such as tuberous sclerosis or Fragile-X syndrome. At USM, exclusion criteria for potential participants with ASD were presence of medical causes of autism on the basis of history, physical exam, Fragile-X gene testing, and karyotyping.  

Inclusion criteria. OLIN required potential ASD and TD participants to meet an intelligence quotient (IQ) cutoff of at least 70 on the full-scale IQ (FIQ), PITT required FIQ>80, USM required performance IQ (PIQ)>70, UM_2 required verbal IQ (VIQ)>=80, and UM_1 required that either VIQ or PIQ scores were >=85. Participants at UCLA_1 were reported to be required to be “fully verbal”; IQ cut-off is not indicated for NYU.
Estimates of IQ (Verbal and Performance IQ) were obtained using the Wechsler Adult Intelligence Scale (WAIS-III) 18 (Wechsler, 1997) at USM, using the Wechsler Abbreviated Scales of Intelligence (WASI) 19 (Wechsler, 1999) at UM_2, USM, NYU, UCLA_1, and PITT and using the Wechsler Intelligence Scale for Children at UCLA_1 (WISC-IV) 20 (Wechsler 2003). Differential Abilities Scale (DAS-II: School Age Edition)(16) was also used at UM_1. At UM_1 and UM_2, estimates were also obtained using the Ravens Standard Progressive Matrices 21 (Raven 1960) and the Peabody Picture Vocabulary Test (PPVT) 22(Dunn & Dunn 1997). 
When using Ravens and the PPVT scales, which estimate performance and verbal IQ, respectively, full IQ estimate is reported as an average of PIQ and VIQ. Only full IQ estimates are reported for the OLIN site using the WAIS-III 18 (Wechsler, 1997) and WISC-III 23 (Wechsler 1991).

Additional inclusion/exclusion site-specific criteria for TD participants. Typically developing participants were required to be neurologically and psychiatrically healthy individuals. UM_1 excluded potential TD participants with scores > 100 on the SCQ or > 6 on the Obsessive/Compulsive Scale of the Spence Children’s Anxiety Scale (SCAS) 24 (Spence 1997). UM_2 screened participants for clinically-significant symptoms using the Achenbach Young Adult (Child) Behavior Checklist 25 , Social Responsiveness Scale-Child version 26 , and the Vineland Adaptive Behavior Scales-II (VABS-II)27 (using parental report for adolescent participants). For adults, Achenbach Behavior Checklist and the Conners rating scale 28 (Conners 2008) self-report forms were used. USM required that potential TD participants had no history of learning disabilities, no history of substance abuse, psychiatric disorder, and no family history of ASD in 1st, 2nd, 3rd degree relatives. NYU required an absence of any Axis-I disorder, confirmed using the Schedule of Affective Disorders and Schizophrenia for Children-Present and Lifetime Version (KSADS-PL)  ADDIN EN.CITE 29 in children and participant interview using the Structured Clinical Interview for DSM-IV-TR Axis-I Disorders, Non-patient Edition (SCID-I/NP) 30 and the Adult ADHD Clinical Diagnostic Scale (ACDS)  ADDIN EN.CITE 31 for adults. OLIN required that ADOS-G and SCQ-Lifetime Version scores were below diagnostic cut-offs for ASD; inclusion was ascertained on the basis of a “detailed health questionnaire”. UCLA_1 required that potential TD participants “could not have a first-degree relative with ASD”.  Pitt required that potential TD participants have no history of birth complications or a psychiatric disorder.  

Inclusion criteria for ASD participants. In determining whether potential participants meet criteria for inclusion in the ASD group, all seven sites used the Autism Diagnostic Observation Schedule (ADOS-G)  ADDIN EN.CITE 16 and the parent interview, Autism Diagnostic Interview-Revised (ADI-R)  ADDIN EN.CITE 17. OLIN used either the ADI-R or the Social Communication Questionnaire (SCQ-Lifetime Version) 32. UM_1, UM_2, and PITT also required a “clinical consensus” or “expert clinical opinion” as the basis for inclusion of participants in the ASD group. Meeting DSM-IV-TR diagnosis of autism was required at USM, and meeting DSM-IV-TR diagnosis of autism, Asperger’s or Pervasive Developmental Disorder Not-Otherwise-Specified (PDD-NOS) was required at NYU.  OLIN required that potential participants had a previous clinical diagnosis of ASD established by a medical professional unaffiliated with Olin. 

Handedness assessments across sites. Handedness was based on either self-report (UM_1, UM_2, and OLIN), Edinburgh Handedness Inventory (Oldfield 1971) 33 (USM and NYU), or Annett Hand Preference Questionnaire 34 (PITT). Numerical scores were converted to categorical variables (Right-handed, left-handed, or ambidextrous). 
Recruitment
ASD and TD participants were recruited from community sources, using advertisements or via referrals. Specific reported recruitment details for each site are presented below. At UM_1 and UM_2, ASD participants were recruited through University of Michigan Autism and Communication Disorder Center (UMACC). TD participants were recruited from the community through flyers. At USM, ASD and TD participants were recruited from community sources (“parent support groups, youth groups, schools, social skills groups, and other organizations”). At NYU, ASD and TD participants were recruited from the New York Metropolitan area, through “flyers, magazine and we advertisements, parent support groups, referrals from the New York University Child Study Center clinical services, as well as word of mouth”. At OLIN, ASD were recruited from the Institute of Living outpatient services and psychiatric clinics in Hartford, Connecticut area. TD were recruited by word of mouth and flyers. At UCLA_1, ASD and TD were recruited from the greater Los Angeles, California area (“using flyers posted in community/youth organizations and schools, radio ads, and word of mouth”). At PITT, ASD participants were individuals with Autistic Disorder, “referred from the Center for Excellence in Autism Research (CEFAR) and the Autism Center of Excellence (ACE). TD participants were recruited from previous studies, by using flyers and announcements” in the community. (http://fcon_1000.projects.nitrc.org/indi/abide/)

Eye status during the resting scan across study-sites
UM_1 and UM_2: Participants were asked to look at a fixation cross in the middle of the screen, and were “instructed to let their minds wander and to not think about anything in particular while they looked at the cross”. USM:  "Keep your eyes open and remain awake, letting thoughts pass through your mind without focusing on any particular mental activity." NYU: “Most participants were asked to relax with their eyes open, while a white cross-hair against a black background was projected on a screen. However, data were also included for some individuals who were asked to keep their eyes closed; in a few cases, participants closed their eyes regardless of instructions to maintain them open.”    OLIN: “Participants were instructed to lie still with their eyes open, fixating on a centrally presented cross”. UCLA_1: Participants were asked to "Relax and think about whatever you want. Keep your eyes open and keep your head still.” A white screen with a black fixation cross in the middle of the screen was presented. PITT:  Participants were “instructed to close their eyes and asked not to fall asleep.” (http://fcon_1000.projects.nitrc.org/indi/abide/)
MRI acquisition parameters 




Open-access, freely accessible Attention Deficit and Hyperactivity Disorder (ADHD-200) database (http://fcon_1000.projects.nitrc.org/indi/adhd200/) was used to obtain datasets with resting-state data of individuals with ADHD and typically developing controls. For all ADHD-200 study-sites, participants signed assent and parental consent forms according to IRB-approved protocol procedures at each institution. Fully anonymized, de-identified datasets (free of the 18 HIPPA identifiers) were analyzed. Analysis of these de-identified data was approved by the Institutional Review Boards of Rutgers University and Columbia University Medical Center. 

Inclusion/exclusion criteria in the current study
ADHD-200 study sites included the New York University Child Study Center (“NYU”), Oregon Health State University (“OHSU”) and Peking (“PEKING”). We included ADHD-200 study-sites that contributed several functional runs per participant (NYU, OHSU) as well as a study-site with a single run (PEKING) whose total duration was at least 8 minutes. Raw, motion-uncorrected data in NIfTI format were downloaded.  Participants with only 1 run at NYU or OHSU were not included in the current study. PEKING study-site consisted of Samples 1 and 2: from the National Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University and Sample 3: from the Institute of Biophysics, Chinese Academy of Sciences (note that scan duration for all PEKING samples was identical: 8 min 6 s, 240 volumes over 1 run).  

Inclusion/exclusion criteria at the study-sites
Study-site specific, detailed inclusion/exclusion criteria for each ADHD-200 site are reported at http://fcon_1000.projects.nitrc.org/indi/adhd200/). We note that criteria are similar, but not identical across all sites, and not directly comparable to those in the ABIDE database. All three sites included children participants with a diagnosis of Attention Deficit Hyperactivity Disorder (ADHD) and Typically Developing (TD) children. Inclusion in the ADHD diagnostic group common to all sites was establishment of ADHD diagnosis based on the administration of the Schedule of Affective Disorders and Schizophrenia for Children—Present and Lifetime Version (KSADS-PL) ADDIN EN.CITE 29 at NYU and PEKING and on KSADS (35;  ADDIN EN.CITE 29) at OHSU, administered to parents and children. Stimulant medication was withheld from ADHD participants for whom it was currently prescribed at all sites. Exclusion criteria for potential ADHD and TD participants across all three sites included contraindications to MRI scanning environment; site-specific criteria are detailed below.  Additional information on the inclusion/exclusion criteria is listed at http://fcon_1000.projects.nitrc.org/indi/adhd200/.

Exclusion criteria for ADHD and TD participants
NYU excluded all potential participants who had “chronic medical conditions”. NYU excluded potential ADHD participants with “a conduct disorder, bipolar and major depressive disorders, and any psychotic disorders”  ADDIN EN.CITE 36. OSHU excluded potential participants with a “history of neurological illness, chronic medical problems, sensorimotor handicap, autistic disorder, mental retardation, or significant head trauma (with loss of consciousness) was identified by parent report, or if they had evidence of psychotic disorder or bipolar disorder on the structured parent psychiatric interview”. Typically developing (TD) control children were excluded for “presence of conduct disorder, major depressive disorder, or history of psychotic disorder, as well as for presence of ADHD”  ADDIN EN.CITE 36. OSHU also reported that participants “were excluded if they did not meet criteria for ADHD or non-ADHD groups (i.e. children deemed sub-threshold by the clinicians were excluded)” (http://fcon_1000.projects.nitrc.org/indi/adhd200/).

Inclusion criteria for ADHD and TD participants
NYU and PEKING required all children participants (ADHD and TD) to meet full-scale intelligence quotient (FSIQ) cut-off above 80. OHSU did not report IQ cutoff. Intelligence quotient (IQ) was estimated using the Wechsler Abbreviated Scale of Intelligence (WASI) (Wechler 1999) at NYU, using a three-subtest short form (Block Design, Vocabulary, and Information) of the Wechsler Intelligence Scale for Children, Fourth Edition (WISC-IV) (Wechler 2003) at OHSU, and using Wechsler Intelligence Scale for Chinese Children-Revised (WISCC-R) (Gong & Cai, 1993) at PEKING. NYU, OSHU and PEKING required all participants to be right-handed. PEKING required that all participants (ADHD and TD) had “no lifetime history of head trauma with loss of consciousness, (iii) no history of neurological disease and no diagnosis of either schizophrenia, affective disorder, pervasive development disorder, or substance abuse, on the basis of KSADS-PL administered to all participants”. For inclusion in the TD group, NYU required “absence of any Axis-I psychopathology on the basis parent and child KSADS-PL interview and T-scores <60 on Conners’ Parent Rating Scale-Revised, Long version (CPRS-R:LV)37 ADHD summary scales”. For all children, NYU required “absence of other chronic medical conditions” (http://fcon_1000.projects.nitrc.org/indi/adhd200/).

Inclusion criteria for the ADHD group: establishment of ADHD diagnosis
Inclusion of participants in the ADHD group required ascertainment of ADHD diagnosis, established on the basis of KSADS administration (“PL” version at NYU and PEKING and “I” version at OHSU) and the following criteria that varied by site. NYU established ADHD diagnosis by requiring potential participants to receive a diagnosis of ADHD on the basis of parent and child responses on the KSADS-PL and to obtain a T-score >=65 on “at least one ADHD related index” of the Conners’ Parent Rating Scale-Revised, Long version (CPRS-R: LV). NYU established ADHD subtypes “based on the interview and review of available records”  ADDIN EN.CITE 36. OHSU established ADHD diagnosis on the basis of KSADS-I, a parent and teacher Connors’ Rating Scale-3rd Edition 38, and via consensus diagnosis by a child psychiatrist and neuropsychologist. PEKING required potential participants (for inclusion in the ADHD group) to be first identified by achieving ADHD diagnosis via the Computerized Diagnostic Interview Schedule IV (C-DIS-IV) 39.  PEKING then established final ADHD diagnosis by administering KSADS-PL. In addition, ADHD symptomology was assessed using the ADHD Rating Scale parent form (ADHD-RS) IV 40 (http://fcon_1000.projects.nitrc.org/indi/adhd200/).

Datasets
Datasets from 503 individuals were downloaded (NADHD=232; NTD=271). The focus of the current analysis is on datasets from 443 participants for whom medication status was available (i.e., status noted as currently on psychotropic medication, or off psychotropic medication), NADHD=175; NTD=268 (total N=443 datasets). None of the TD participants were currently taking psychotropic medication. Out of 175 ADHD participants, 114 were not currently on medication, while 61 were on some type of psychotropic medication. Specific medication class or name was not available in ADHD-200 database. The 443 datasets from the three sites break down as: NYU (NADHD =45; NTD =86), OHSU (NADHD =28; NTD =39), and PEKING (NADHD =102; NTD =143) (Total: NADHD =175, NTD =268). 

Demographic characteristics
ADHD datasets. Participants at the three main sites (NYU, OHSU, PEKING) did not differ in age 11.40 (2.56) (mean and standard deviation; range: 7.17-17.96) for the ADHD group, and 11.60 (2.49) (range: 7.24-17.43) for the TD group (p=0.41). 172 ADHD participants were right-handed and 3 were left-handed; 260 TD participants were right-handed and 4 were left-handed. Scores were missing for 4 TD participants.

Stimulant withholding information
For participants in the ADHD group who were currently taking psychostimulant medications, NYU reported that such medications “were withheld at least 24 hours before scanning”. OHSU reported a “minimum washout of five half-lives” before children on short-acting stimulants were scanned (a period of 24-48 hours;  ADDIN EN.CITE 36). PEKING reported withholding of psychostimulants for “at least 48 hours prior to scanning” (http://fcon_1000.projects.nitrc.org/indi/adhd200/).

Specific instructions to participants during the resting scan (eye status)
OHSU: Participants were “instructed to stay still, and fixate on a standard fixation-cross in the center of the display”  ADDIN EN.CITE 36. NYU: Participants were “instructed to lie still and relax with their eyes open, while a standard fixation-cross was presented in the center of the display”  ADDIN EN.CITE 36. PEKING: Peking Sample 3: Participants were instructed to “simply remain still, close their eyes, think of nothing systematically, and not fall asleep”  ADDIN EN.CITE 36. Eye status information was not available for PEKING Samples 1 and 2 (http://fcon_1000.projects.nitrc.org/indi/adhd200/). 
MRI acquisition parameters
BOLD signal was obtained with T2*-weighted echo planar imaging (EPI) sequence for all three ADHD-200 study-sites used in the current study. At NYU Child Study Center, EPI sequence parameters were: [TR (Repetition Time) /TE (Echo Time): 2000/15 ms, flip angle=90°, FOV (Field of View) =220 mm (read) x 192 mm (phase), 80 x 80 matrix, 33 contiguous axial 4 mm thick slices], with interleaved slice acquisition and no gap between slices. Scan duration of each run was 6 min (180 volumes), for a total scan duration at NYU of 12 min (360 volumes over 2 runs). At Oregon Health Sciences University (OHSU), EPI parameters were: [TR/TE: 2500/30 ms, flip angle=90°, FOV=240 mm (read) x 240 mm (phase), 64 x 64 matrix, 36 axial 3.8 mm slices], with interleaved slice acquisition and no gap between slices. Scan duration of each run was 3.32 min (82 volumes), for a total scan duration at OHSU of 9.96 min (246 volumes over 3 runs). PEKING was comprised of Samples 1 and 2, from the National Key Laboratory of Cognitive Neuroscience and Learning, Beijing Normal University and Sample 3, from the Institute of Biophysics, Chinese Academy of Sciences. At Peking Sample 1 (“PEKING_1”), EPI parameters were: [TR/TE: 2000/30 ms, flip angle=90°, FOV=200 mm (read) x 200 mm (phase), 64 x 64 matrix, 33 axial 3.5 mm slices], with interleaved slice acquisition and 0.7 mm gap between slices. At Peking Sample 2 (“PEKING_2”), EPI parameters were: [TR/TE: 2000/30 ms, flip angle=90°, FOV=200 mm (read) x 200 mm (phase), 64 x 64 matrix, 33 axial 3 mm slices], with interleaved slice acquisition and 0.6 mm gap between slices. At Peking Sample 3 (“PEKING_3”), EPI parameters were: [TR/TE: 2000/30 ms, flip angle=90°, FOV=200 mm (read) x 200 mm (phase), 64 x 64 matrix, 30 axial 4.5 mm slices], with interleaved slice acquisition and no gap between slices. Scan duration for all PEKING samples was 8 min 6 s (240 volumes over 1 run) (http://fcon_1000.projects.nitrc.org/indi/adhd200/).

Head Movement Estimates 
The overall approach involves first linearizing the problem (expansions via smooth basis functions, polynomials and first order Taylor series) in order to find a least squares solution that minimizes the differences between the two images following simultaneous spatial and intensity transformations. We briefly outline key aspects of the approach; detailed treatment is given by Karl Friston and colleagues in41. 

Here the problem is that of aligning a given volume image (“object” or “observed” image) so that it matches, as best as possible, another image (“template” or “reference” image).  Potential differences between an object image and a reference image can be partitioned into two components: those due to (1) voxel intensity differences when the images are in full anatomical congruence with each other and (2) misalignment or spatial discrepancy41.
These differences are partitioned according to the expression, Equation 1 in Friston et al., 1995, 
, (Equation 1)
where  is the template or reference image, and  is observed image;  is an error term. This expression says that the “two images can be approximated by applying an intensity transformation  to one and a spatial transformation  to the other” (Friston et al., 1995). The is an intensity operator that “maps voxel values from one image to another at point ” while  denotes the spatial transformation between the two images41.  

Low-order approximations and constraints are imposed on the form of  and  simultaneously in order to linearize Equation 1 (so as to obtain a least squares solution)41. Specific constraints governing expansions “relate to preservation of local contiguity relationships and local stationariness of the intensity transformation”41. The two important constraints on and  are as follows:  can be “expressed in terms of a convolution and a (nonstationary) linear function and both  and  change slowly with location”41. The characteristic that “ can change with position but is similar within a given locale”  ADDIN EN.CITE 42-44 embodies the local stationariness assumption, meaning that “something does not change with position in the image”  ADDIN EN.CITE 42-44. Further, the fact that  undergoes slow changes means that the “spatial transformation is smooth and that local contiguity relationships are preserved”  ADDIN EN.CITE 42-44.   

Equation #4 in 41 is read as follows, quoted from the paper: “One image can be approximated to another by (1) applying an intensity transformation to the first image (where the coefficients of the transformation expansion’s can change slowly with position), convolving, and (2) approximating the distortion of the second image by simply adding the effects of each component of the distortion (assuming the components are small relative to the image’s resolution”41. Because this equation is linear in the unknown coefficients ( and ), these coefficients have a unique least squares solution41 
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